ACACA and fatty liver disease: In summary, we demonstrated that dapagliflozin ameliorates hepatic steatosis by decreasing the de novo lipogenesis enzyme ACC1, increasing the fatty acid oxidation enzyme ACOX1 and inducing autophagy.